Weekly Cosmetic Research Analysis
This week’s cosmetic research highlights three high-impact clinical and translational advances: (1) a multicenter randomized phase II trial showing a bio‑engineered autologous dermo‑epidermal graft (denovoSkin) improves scar quality versus split‑thickness grafts; (2) a novel tri‑functional injectable bioadhesive (CMCS/γ‑PGA/PRP) with antibacterial, adhesive, and regenerative properties that speeds infected wound healing in preclinical models; and (3) a double‑blind RCT with mechanistic transcrip
Summary
This week’s cosmetic research highlights three high-impact clinical and translational advances: (1) a multicenter randomized phase II trial showing a bio‑engineered autologous dermo‑epidermal graft (denovoSkin) improves scar quality versus split‑thickness grafts; (2) a novel tri‑functional injectable bioadhesive (CMCS/γ‑PGA/PRP) with antibacterial, adhesive, and regenerative properties that speeds infected wound healing in preclinical models; and (3) a double‑blind RCT with mechanistic transcriptomics supporting a topical San‑Bai decoction extract for UV protection. Together these studies emphasize translational biomaterials, integrated mechanistic evaluation of cosmeceuticals, and clinically meaningful outcomes for aesthetic and reconstructive care.
Selected Articles
1. Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial.
In a multicenter phase II randomized intra‑patient controlled trial (n=23), denovoSkin™, a bio‑engineered autologous dermo‑epidermal graft cultured in an extracellular matrix, produced significantly better observer‑rated scar quality at 3 months versus paired split‑thickness skin grafts, with demonstrated feasibility and safety over 1 year.
Impact: Provides randomized, intra‑patient controlled clinical evidence that a tissue‑engineered autologous skin substitute can improve scar outcomes and reduce donor‑site morbidity compared with standard split‑thickness grafting.
Clinical Implications: Surgeons treating full‑thickness defects and burn scars should consider denovoSkin as a potential alternative to STSG pending phase III confirmation; it may reduce donor morbidity and improve cosmetic scar outcomes—important in reconstructive planning and patient counseling.
Key Findings
- Randomized intra‑patient controlled multicenter phase II design with 23 patients receiving both denovoSkin and STSG on comparable wounds.
- Observer-rated POSAS total score at 3 months favored denovoSkin (23.4) over STSG (27.9), indicating improved scar quality.
2. An Injectable CMCS/γ-PGA/PRP Bioadhesive With Antibacterial, Adhesive, and Regenerative Properties for Infected Wound Healing.
A preclinical study developed an injectable bioadhesive (CγR) combining carboxymethyl chitosan, γ‑polyglutamic acid, and autologous PRP to yield >99.9% bactericidal activity, rapid wet‑tissue adhesion (>3 kPa), sustained PDGF/TGF‑β/VEGF release, and, in infected rat full‑thickness wounds, sterile sealing with complete epithelialization by day 6 and enhanced collagen deposition and M2 macrophage polarization.
Impact: Condensing suture, antibiotic, and dressing functions into a single, scalable biomaterial platform that integrates antimicrobial activity with regenerative signaling could materially change management of contaminated wounds in aesthetic and reconstructive settings.
Clinical Implications: If translated to humans, the bioadhesive could offer a one‑step alternative for contaminated traumatic and surgical wounds in plastic/reconstructive practice, potentially reducing infection rates and accelerating healing; human toxicology and randomized trials are necessary.
Key Findings
-
99.9% bactericidal efficacy against E. coli and S. aureus and instantaneous wet‑tissue adhesion >3 kPa.
- In infected rat wounds, single application achieved sterile sealing and complete epithelialization within 6 days, with increased collagen deposition and M2 macrophage polarization.
3. Mechanisms underlying the protective effects of San-Bai decoction against UV radiation on the skin.
An integrated in silico–in vitro–in vivo study including a double‑blind, placebo‑controlled clinical trial found a 5% aqueous San‑Bai decoction extract (USBT2627) reduced UV‑induced erythema and improved colorimetric indices (L, ITA°) versus placebo; mechanistic transcriptomics implicated ET‑1, pigmentation, oxidative stress, and cytokine pathways.*
Impact: Rare example of a double‑blind, placebo‑controlled cosmeceutical RCT coupled with mechanistic transcriptomics—provides objective clinical endpoints and biological plausibility supporting topical botanical photoprotection.
Clinical Implications: Supports further development and clinical evaluation of this topical as an adjunctive photoprotective strategy; encourages embedding mechanistic biomarkers in early cosmeceutical trials to de‑risk product development.
Key Findings
- 5% USBT2627 pretreatment increased L* (p=0.048) and ITA° (p=0.022) and reduced erythema (p=0.016) under UV exposure versus placebo.
- Transcriptomic profiling linked effects to modulation of ET‑1 signaling, pigmentation pathways, oxidative response, and cytokine signaling.